Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data mimics heart trial for diabetes drugs

NCT ID NCT07088718

Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether healthcare claims data can predict the results of a major heart trial (SURPASS-CVOT) comparing two diabetes drugs, tirzepatide and dulaglutide. Researchers analyzed records from over 44,000 people with type 2 diabetes and heart disease to see if real-world data could reliably mimic the trial's findings. The goal is to understand when real-world data can be trusted for clinical research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide and dulaglutide
What this could lead to
If successful, this could show that analyzing real-world patient data can reliably predict the outcomes of large clinical trials, potentially speeding up future research.
What could go wrong
This is an observational study using existing data, not a controlled experiment. Results may not perfectly match the original trial due to differences in patient populations or data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

44,671 people

The number who actually took part.

Started

Oct 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals aged 40 years or older with T2DM and an established CVD

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

FOLLOWING ELIGIBILITY CIRTERIA OF THE SURPASS-CVOT TRIAL Inclusion Criteria: * History of MI, surgical or percutaneous coronary/carotid peripheral artery revascularization * BMI ≥25.0kg/m2 * Type 2 diabetes, diagnosis of coronary/carotid/peripheral artery disease * Age ≥40 years * Male or female sex Exclusion Criteria: * Medullary thyroid carcinoma, MEN syndrome type 2, malignancy * Treatment for diabetic retinopathy//macular edema, pancreatitis, gastric emptying abnormality/bariatric surgery, liver disease, end-stage renal disease or dialysis, pregnancy * Prior use of pramlintide or any GLP-1-RA except tirzepatide or dulaglutide * Cardiovascular event, hospitalization for heart failure * Concurrent use of both drugs i.e. tirzepatide and dulaglutide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular (CV) risk are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular (CV) risk Major adverse cardiac events Type 2 diabetes

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.